We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Vanda Pharmaceuticals Inc | NASDAQ:VNDA | NASDAQ | Common Stock |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| -0.02 | -0.40% | 4.99 | 4.50 | 5.40 | 5.08 | 4.87 | 5.00 | 1,384,022 | 05:00:08 |
From Nov 2023 to May 2024
By Stephen Nakrosis
Vanda Pharmaceuticals said the Food and Drug Administration accepted the filing of the company's new drug application for tradipitant to treat symptoms of gastroparesis.
Gastroparesis is characterized by delayed gastric emptying with symptoms including bloating, nausea, vomiting and abdominal pain, the company said Monday.
Vanda said about 6 million patients in the U.S. have gastroparesis, many of whom remain undiagnosed.
Write to Stephen Nakrosis at stephen.nakrosis@wsj.com
(END) Dow Jones Newswires
December 04, 2023 18:30 ET (23:30 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.
1 Year Vanda Pharmaceuticals Chart |
1 Month Vanda Pharmaceuticals Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
